摘要
背景:淀粉样β(Aβ)诱导的线粒体功能障碍是阿尔茨海默病神经元毒性的主要原因之一。最近的一些报告表明,线粒体的改变通过细胞内聚集的低聚Aβ。这些改变包括增加线粒体活性氧(ROS),线粒体DNA的损耗,降低氧化磷酸化和ATP的产生,细胞膜去极化,降低线粒体等所有这些缺陷累积导致细胞能量平衡的神经毒变异数。另一方面,消炎药报告促进线粒体生物合成和改善细胞能量状 方法:综合上述线索,我们评价阿司匹林对β42诱导的毒性和线粒体分化的保护作用。 结果:aβ42处理的细胞明显减少,细胞凋亡增加,MTT法、细胞凋亡ELISA和神经元细胞β-微管蛋白抗体免疫荧光染色明显。在Mitotracker Red FM染色和线粒体DNA的强度观察nDNA比也随之减少,提示线粒体膜去极化和/或减少线粒体数目随着线粒体DNA缺失。然而,同时处理5μm的阿司匹林对低聚Aβ42处理的细胞保护他们免受线粒体功能障碍和神经毒性。 结论:我们建议线粒体生物合成、线粒体膜电位的改变和(或)阿司匹林对β42聚集的抑制作用作为可能的机制
关键词: 阿司匹林,oligomeric-aβ42,EC P19细胞,线粒体功能障碍,神经毒性,线粒体DNA和RNA
Current Alzheimer Research
Title:Protective Effect of Aspirin Against Oligomeric Aβ42 Induced Mitochondrial Alterations and Neurotoxicity in Differentiated EC P19 Neuronal Cells
Volume: 14 Issue: 8
关键词: 阿司匹林,oligomeric-aβ42,EC P19细胞,线粒体功能障碍,神经毒性,线粒体DNA和RNA
摘要: Background: Amyloid-beta (Aβ) induced mitochondrial dysfunction is one of the major causes of neuronal toxicity in Alzheimer’s disease. A number of recent reports suggest involvement of mitochondrial alterations through intracellular accumulation of oligomeric Aβ. These mitochondrial alterations include increased Reactive Oxygen Species (ROS), mt-DNA depletion, decreased oxidative phosphorylation and ATP production, membrane depolarization, reduced number of mitochondria etc. All these defects cumulatively caused neural toxicity and alterations in cellular energy homeostasis. On the other hand, anti-inflammatory drug aspirin is reported to promote both mitochondrial biogenesis and improvement in cellular energy status.
Methods: Taking altogether the mentioned clues, we evaluated protective effect of aspirin, if any on oligomeric Aβ42 induced toxicity and mitochondrial alterations in differentiated neuronal cells. Results: A significant reduction in neuronal viability and increased apoptosis was observed in Aβ42 treated cells, as evident by MTT assay, apoptosis ELISA and immunofluorescence from β-III tubulin antibody staining of neuronal cells. A concomitant decrease was also observed in the intensity of mitotracker red FM staining and mt-DNA to nDNA ratio, suggesting mitochondrial membrane depolarization and/or reduced number of mitochondria along with depletion in mt-DNA. However, simultaneous treatment of 5 μM aspirin to oligomeric Aβ42 treated cells protected them from mitochondrial dysfunction and neurotoxicity. Conclusion: We suggest mitochondrial biogenesis, changes in mitochondrial membrane potential and / or inhibition of Aβ42 aggregation by aspirin as possible underlying mechanism(s).Export Options
About this article
Cite this article as:
Protective Effect of Aspirin Against Oligomeric Aβ42 Induced Mitochondrial Alterations and Neurotoxicity in Differentiated EC P19 Neuronal Cells, Current Alzheimer Research 2017; 14 (8) . https://dx.doi.org/10.2174/1567205014666170203104757
DOI https://dx.doi.org/10.2174/1567205014666170203104757 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Co-opting Functions of Cholinesterases in Neural, Limb and Stem Cell Development
Protein & Peptide Letters Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Characterization of Fiber-Forming Peptides and Proteins by Means of Atomic Force Microscopy
Current Protein & Peptide Science Real Time Analysis of Neurotransmitters in the Brain Using a Micro-Electrode System
Current Neurovascular Research High-throughput Screening Identifies Small Molecule Inhibitors of Molecular Chaperones
Current Pharmaceutical Design Akt Pathway Inhibitors
Current Topics in Medicinal Chemistry Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Non-Cholinergic Pharmacotherapy Approaches to Alzheimers Disease: The Use of Non-Steroidal Anti-Inflammatory Drugs
CNS & Neurological Disorders - Drug Targets Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA A Medicinal Chemist’s Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents
Current Topics in Medicinal Chemistry An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome
Current Alzheimer Research Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Brain Nitric Oxide and Its Dual Role in Neurodegeneration / Neuroprotection: Understanding Molecular Mechanisms to Devise Drug Approaches
Current Medicinal Chemistry New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued)